Kapstone Financial Advisors LLC grew its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 1.5% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,045 shares of the company’s stock after buying an additional 208 shares during the period. AbbVie accounts for 1.6% of Kapstone Financial Advisors LLC’s portfolio, making the stock its 15th biggest holding. Kapstone Financial Advisors LLC’s holdings in AbbVie were worth $2,409,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vermillion & White Wealth Management Group LLC bought a new stake in AbbVie in the 4th quarter worth approximately $26,000. Ridgewood Investments LLC bought a new stake in AbbVie in the second quarter worth $27,000. Able Wealth Management LLC purchased a new stake in AbbVie during the fourth quarter valued at $33,000. IFS Advisors LLC bought a new position in AbbVie during the first quarter valued at $36,000. Finally, Ables Iannone Moore & Associates Inc. purchased a new position in shares of AbbVie in the 4th quarter worth $37,000. 70.23% of the stock is owned by hedge funds and other institutional investors.
AbbVie Stock Down 0.9 %
AbbVie stock traded down $1.77 during mid-day trading on Thursday, reaching $195.24. 190,804 shares of the company were exchanged, compared to its average volume of 5,399,649. The company has a debt-to-equity ratio of 8.51, a quick ratio of 0.71 and a current ratio of 0.81. The firm has a market cap of $344.77 billion, a P/E ratio of 58.46, a PEG ratio of 2.68 and a beta of 0.64. AbbVie Inc. has a 12-month low of $135.85 and a 12-month high of $199.95. The business has a fifty day moving average of $182.97 and a 200 day moving average of $174.37.
AbbVie Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Thursday, August 15th. Stockholders of record on Monday, July 15th were given a dividend of $1.55 per share. This represents a $6.20 dividend on an annualized basis and a dividend yield of 3.18%. The ex-dividend date was Monday, July 15th. AbbVie’s payout ratio is presently 183.98%.
Analysts Set New Price Targets
A number of research analysts recently commented on ABBV shares. Barclays increased their price target on shares of AbbVie from $187.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, July 26th. Wells Fargo & Company boosted their target price on AbbVie from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Friday, July 26th. Piper Sandler raised their price target on AbbVie from $196.00 to $209.00 and gave the stock an “overweight” rating in a research report on Friday, August 23rd. Piper Sandler Companies reiterated an “overweight” rating and set a $190.00 price target on shares of AbbVie in a report on Wednesday, July 3rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $200.00 target price on shares of AbbVie in a research note on Monday, August 5th. Two investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and an average target price of $191.64.
Read Our Latest Stock Analysis on AbbVie
Insider Activity
In related news, Chairman Richard A. Gonzalez sold 66,500 shares of the company’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $186.52, for a total transaction of $12,403,580.00. Following the transaction, the chairman now directly owns 446,599 shares of the company’s stock, valued at approximately $83,299,645.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other AbbVie news, Chairman Richard A. Gonzalez sold 66,500 shares of the company’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $186.52, for a total transaction of $12,403,580.00. Following the transaction, the chairman now owns 446,599 shares in the company, valued at approximately $83,299,645.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Richard A. Gonzalez sold 282,845 shares of AbbVie stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $175.00, for a total transaction of $49,497,875.00. Following the sale, the chairman now owns 513,099 shares of the company’s stock, valued at $89,792,325. The disclosure for this sale can be found here. Company insiders own 0.25% of the company’s stock.
AbbVie Company Profile
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Recommended Stories
- Five stocks we like better than AbbVie
- How to Invest in Small Cap StocksÂ
- Why NVIDIA Is More of a Screaming Buy Than Ever
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Don’t Miss These 3 Stocks Set to Defy Expectations in September
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Top 3 Emerging Market ETFs to Watch as the U.S. Dollar Weakens
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.